

Sc Inj
SC Infusion 0.5 mpk
#1A
#1B
#1C
#5A
#5B
#5C
Mean RM-493 (ng/mL)
Time (hr)
SC Inj
SC Infusion 0.5 mpk
1A
5B
5A
5C
1B
1C
0
200
400
600
800
1000
1200
0
10
20
30
40
50
60
70
80

FIG. 1A



Sc Inj
SC Infusion 0.5 mpk
#1A
#1B
#1C
#5A
#5B
#5C
SC Infusion 0.5 mpk
1A
5A
5B
5C
SC Inj
1B
1C
Mean RM-493 (ng/mL)
10000
1000
100
10
1
0
10
20
30
40
50
60
70
80
Time (hr)

FIG. 1B



Mean RM-493 (ng/mL)
180
160
140
120
100
80
60
40
20
0
0
50
100
150
200
250
Time (hr)
#1D
#1E
#5D
SC Infusion 0.5 mpk
SC Infusion 0.5 mpk
1D
1E
5D

FIG. 2A



Mean RM-493 (ng/mL)
1000
100
10
0
50
100
150
200
250
Time (hr)
SC Infusion 0.5 mpk
1D
1E
5D
#1D
#1E
#5D
SC Infusion 0.5 mpk

FIG. 2B



30 mg Single Dose
10 mg Single Dose
2.5 mg Single Dose
Mean Setmelanotide Concentration (ng/mL) in Plasma
100
10
1
0.1
0.01
0
48
96
144
192
240
288
336
384
432
480
528
576
624
Nominal Time (hr)

FIG. 3



Setmelanotide Concentration (ng/mL) in Plasma
0
1
2
3
4
5
0
2
4
6
8
10
12
14
16
18
20
22
24
26
28
30
Time (Day)
Subject 203
Subject 204
Subject 205
Subject 207
Subject 209
Subject 210

FIG. 4



30 mg/mL Commercial Grade GDO
30 mg/mL Purified Commercial Grade GDO
30 mg/mL Synthetic GDO
% Setmelanotide degradation
(increase from T=0)
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
0
0.5
1
1.5
2
2.5
3
Months at 40°C

FIG. 5



30 mg/mL Commercial Grade GDO + High EDTA
30 mg/mL Purified Commercial Grade GDO + High EDTA
30 mg/mL Synthetic GDO + High EDTA
% Setmelanotide degradation
(increase from T=0)
3.0
2.5
2.0
1.5
1.0
0.5
0.0
0
0.5
1
1.5
2
2.5
3
Months at 40°C

FIG. 6



30 mg/mL Purified Commercial Grade GDO + High EDTA
30 mg/mL Synthetic GDO + High EDTA
15 mg/mL Purified Commercial Grade GDO + High EDTA
15 mg/mL Synthetic GDO + High EDTA
% Setmelanotide degradation
(increase from T=0)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
0
0.5
1
1.5
2
2.5
3
Months at 40°C

FIG. 7